The success of checkpoint inhibitors has accelerated the clinical implementation of a vast
mosaic of single agents and combination immunotherapies. However, the lack of clinical …

The T cell infiltrates that are formed in human cancers are a modifier of natural disease
progression and also determine the probability of clinical response to cancer …

The overall response rate for anti–PD-1 therapy remains modest in hepatocellular
carcinoma (HCC). We found that a combination of IFNα and anti–PD-1–based …

Immune checkpoint blockade is able to induce durable responses across multiple types of
cancer, which has enabled the oncology community to begin to envision potentially curative …

Various forms of immunotherapy, such as checkpoint blockade immunotherapy, are proving
to be effective at restoring T cell-mediated immune responses that can lead to marked and …

Therapeutic reinvigoration of tumor-specific T cells has greatly improved clinical outcome in
cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence …

Immunotherapy plays an increasingly important role in the treatment of most malignant
tumors, and CD8+ T cells are the most important antitumor effector cells in the process of …

Despite impressive durable responses, immune checkpoint inhibitors do not provide a long-
term benefit to the majority of patients with cancer. Understanding genomic correlates of …

Although current immune-checkpoint therapy (ICT) mainly targets lymphoid cells, it is
associated with a broader remodeling of the tumor micro-environment. Here, using …

Abstract Treatment of high-grade serous ovarian cancer (HGSOC) remains challenging.
Although HGSOC can potentially be responsive to immunotherapy owing to endogenous …